Loading…
Loading…
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
The Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to 26 for the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF currently offers a significantly higher dividend yield and a lower expense ratio than its counterpart.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
VanEck Pharmaceutical ETF offers a lower-volatility profile and a higher 1.9% dividend yield compared to State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF provides broad exposure with 155 holdings, whereas VanEck Pharmaceutical ETF is concentrated in 26 major drugmakers.
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.